HIV news from aidsmap.com

By | December 4, 2019

HIV news from aidsmap.comhttp://www.aidsmap.com/feeds/latest-hiv-news en <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Flawed definitions of unsafe sex massively over-estimate how many people are having it <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –>http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/dec-2019/flawed-definitions-unsafe-sex-massively-over-estimate-how-many-people-are-having-it_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> The proportion of HIV-positive gay and bisexual men having ‘unsafe sex’ falls from 42% to 2% when a nuanced definition of the term is used, Dr Keith Horvath of the University of Minnesota and colleagues report in the Archives of Sexual Behaviour. “Traditional definitions of sexual risk (condomless anal sex or condomless anal sex with a serodiscordant partner) may not suffice, given the success of biomedical prevention in the absence of condoms,” they say. <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Roger Pebody http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/dec-2019/flawed-definitions-unsafe-sex-massively-over-estimate-how-many-people-are-having-it_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ Epidemiology & behaviour HIV prevention policy Roger Pebody <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> People with HIV aged 75 and older receiving good HIV care but many at risk of frailty <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –>http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/dec-2019/people-hiv-aged-75-and-older-receiving-good-hiv-care-many-risk-frailty_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> People with HIV aged 75 years and older are receiving “almost perfectly managed” care, but are more likely to experience age-related health conditions, according to French research published in Médecine et maladies infectieuses. <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Michael Carter http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/dec-2019/people-hiv-aged-75-and-older-receiving-good-hiv-care-many-risk-frailty_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ Epidemiology & behaviour HIV prevention policy Roger Pebody <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> aidsmapLIVE: World AIDS Day special <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –>http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/dec-2019/aidsmaplive-world-aids-day-special_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> On Tuesday 26 November, we hosted a World AIDS Day aidsmapLIVE special, part of our series of live panel discussions broadcast on social media. aidsmapLIVE: The past, present &amp; future of HIV gave us the opportunity to remember those we’ve lost, consider the challenges we face today and look to the future for upcoming advances in HIV. Our panel members were Jide Macaulay, Jonathan Blake, Dr Steve Taylor, Becky Kroger, Rebecca De Havilland and NAM’s Matthew Hodson. NAM’s Susan Cole hosted the event.  <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Amelia Jones http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/dec-2019/aidsmaplive-world-aids-day-special_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ Epidemiology & behaviour HIV prevention policy Roger Pebody <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Poor physical growth a common problem among HIV-positive adolescents in low- and middle-income countries <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –>http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/poor-physical-growth-common-problem-among-hiv-positive-adolescents-low-and-middle_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> There is a high prevalence of stunted physical growth among HIV-positive adolescents living in low- and middle-income countries, investigators report in the Journal of the International AIDS Society. Approximately 50% had stunted growth at the time antiretroviral therapy (ART) was started. After the age of 12 years, adolescent boys were especially likely to have poorer than expected growth. <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Michael Carter http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/poor-physical-growth-common-problem-among-hiv-positive-adolescents-low-and-middle_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ Epidemiology & behaviour HIV prevention policy Roger Pebody <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Effectiveness and frequency of dosing are the most important factors affecting acceptability of injectable HIV therapy, says US study <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –>http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/effectiveness-and-frequency-dosing-are-most-important-factors-affecting-acceptability_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Effectiveness and dosing frequency are the two key factors affecting the acceptability of long-acting injectable antiretroviral therapy, according to a small study conducted in the United States and published in AIDS and Behavior. Participants found injectable treatment moderately acceptable. The study included a broad spectrum of people living with HIV, including individuals with adherence problems, a likely target population for long-acting injectable therapy should it become available. <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Michael Carter http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/effectiveness-and-frequency-dosing-are-most-important-factors-affecting-acceptability_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ Epidemiology & behaviour HIV prevention policy Roger Pebody <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Why do gay men do chemsex? <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –>http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/why-do-gay-men-do-chemsex_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Stéphane, a volunteer with the French community organisation AIDES, set the tone for the recent 3rd European ChemSex Forum in Paris when he explained why he continues to use drugs in sexual situations. There are multiple reasons, many of them shared by other people, he said. “Firstly, the idea of pleasure is essential,” he said. “There is also the fear of not being able to do without, as well as the fear of not being up to the mark. <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Roger Pebody http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/why-do-gay-men-do-chemsex_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ Epidemiology & behaviour HIV prevention policy Roger Pebody <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Mystery shopper exercise shows that HIV testing services for young gay men in the US need to be improved <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –>http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/mystery-shopper-exercise-shows-hiv-testing-services-young-gay-men-us-need-be-improved_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> A quality assurance exercise using ‘mystery shoppers’ in three US cities with high HIV incidence among young gay men showed that although most testing sites were perceived as welcoming, friendly and confidential, other problems were identified. Testing sites performed poorly on LGBTQ visibility, only a minority discussed relationship contexts or provided safer sex education, and information about PrEP was inconsistently provided. The study is published in the 1 December issue of the Journal of Acquired Immune Deficiency Syndromes. <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Michael Carter http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/mystery-shopper-exercise-shows-hiv-testing-services-young-gay-men-us-need-be-improved_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ Epidemiology & behaviour HIV prevention policy Roger Pebody <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Vigilance over HIV drug interactions still needed <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –>http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/vigilance-over-hiv-drug-interactions-still-needed_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Problematic interactions between antiretroviral drugs and other medications remain a substantial challenge for people with HIV despite the shift away from the use of boosted protease inhibitors and older non-nucleoside reverse transcriptase inhibitors, research presented at the 17th European AIDS Conference earlier this month showed. <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Keith Alcorn http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/vigilance-over-hiv-drug-interactions-still-needed_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ Epidemiology & behaviour HIV prevention policy Roger Pebody <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Tesamorelin reduces liver fat and fibrosis progression in people with HIV and non-alcoholic fatty liver disease <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –>http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/tesamorelin-reduces-liver-fat-and-fibrosis-progression-people-hiv-and-non-alcoholic_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Treatment with tesamorelin, a synthetic growth hormone-releasing hormone, reduced liver fat content and reduced the progression of liver fibrosis in people with HIV who had non-alcoholic fatty liver disease, researchers report in The Lancet HIV. <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Keith Alcorn http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/tesamorelin-reduces-liver-fat-and-fibrosis-progression-people-hiv-and-non-alcoholic_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ Epidemiology & behaviour HIV prevention policy Roger Pebody <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Second case of unintended HIV transmission during HIV cure study prompts questions about PrEP provision <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –>http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/second-case-unintended-hiv-transmission-during-hiv-cure-study-prompts-questions-about_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> A second case of HIV transmission from someone interrupting their HIV therapy as part of a cure study has been published. The report, by Dr Ainoa Ugarte, Dr Lorna Leal and colleagues from Barcelona University Hospital (Ugarte reference below) has prompted discussion about whether the HIV-negative partners of people involved in studies that feature so-called analytical treatment interruptions should be offered PrEP as a matter of course. <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Gus Cairns http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/second-case-unintended-hiv-transmission-during-hiv-cure-study-prompts-questions-about_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ Epidemiology & behaviour HIV prevention policy Roger Pebody <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Intermittent and lower-risk PrEP users may not be testing for HIV and STIs, German study finds <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –>http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/intermittent-and-lower-risk-prep-users-may-not-be-testing-hiv-and-stis-german-study_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> A survey of German PrEP users reported at the recent 17th European AIDS Conference (EACS 2019) found that one in nine of them had not had a single HIV, STI or renal function test during the time they were on PrEP. Of those who had taken an HIV test while on PrEP, 15.5% had taken a test less often than the recommended interval of three months, and 8.5% had had an STI check-up less often than the recommended once every six months. One in 25 PrEP users had not even had an HIV test shortly before starting PrEP. <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Gus Cairns http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/intermittent-and-lower-risk-prep-users-may-not-be-testing-hiv-and-stis-german-study_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ Epidemiology & behaviour HIV prevention policy Roger Pebody <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> PrEP users have less HIV anxiety <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –>http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/prep-users-have-less-hiv-anxiety_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Several qualitative studies have already found that gay and bisexual men using the preventative medication PrEP have reported benefits in terms of reduced anxiety about HIV, but until now there has been scarcely any quantitative data to confirm this. Now, an Australian study shows a statistically significant reduction in HIV anxiety among men who were eligible for PrEP and who were using it. <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Roger Pebody http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/prep-users-have-less-hiv-anxiety_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ Epidemiology & behaviour HIV prevention policy Roger Pebody <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> One-third of people living with HIV in rural Tanzania report clinically relevant drug-drug interactions <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –>http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/one-third-people-living-hiv-rural-tanzania-report-clinically-relevant-drug-drug_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> A study from rural Tanzania, published online ahead of print in HIV Medicine, provides more evidence on the importance of appropriate management of clinically relevant drug-drug interactions for people living with HIV who are on antiretroviral therapy (ART). As life expectancy of people living with HIV has increased due to improved access to ART, co-morbidities and co-medications are also on the rise. But appropriate management of clinically relevant drug-drug interactions is sub-optimal, especially in low-resource settings. <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Shobha Shukla, Bobby Ramakant http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/one-third-people-living-hiv-rural-tanzania-report-clinically-relevant-drug-drug_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ Epidemiology & behaviour HIV prevention policy Roger Pebody <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Serosorting between gay men may be in decline as ‘PrEP sorting’ rises, Canadian study finds <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –>http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/serosorting-between-gay-men-may-be-decline-prep-sorting-rises-canadian-study-finds_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> A Canadian study which compared the HIV status of gay men’s recent sexual partners with what would be expected if they chose partners regardless of status has found that HIV-negative men who used PrEP were nearly twice as likely to have HIV-positive partners as those who did not. It also found that men using PrEP were more likely to have sex with other PrEP users than with men not using PrEP. Conversely, non-users were more likely to have sex with non-users. <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Gus Cairns http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/serosorting-between-gay-men-may-be-decline-prep-sorting-rises-canadian-study-finds_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ Epidemiology & behaviour HIV prevention policy Roger Pebody <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Rates of pneumonia and pneumococcal disease remain high among people with HIV <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –>http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/rates-pneumonia-and-pneumococcal-disease-remain-high-among-people-hiv_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> The incidence of invasive pneumococcal disease and community-acquired pneumonia remains high among people living with HIV, investigators from the Netherlands report in Clinical Infectious Diseases. Rates of these serious infections were highest among people not taking anti-HIV drugs and with CD4 cell count below 500. <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Michael Carter http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/rates-pneumonia-and-pneumococcal-disease-remain-high-among-people-hiv_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ Epidemiology & behaviour HIV prevention policy Roger Pebody <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Hepatitis C incidence is low among Canadian men on PrEP <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –>http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/hepatitis-c-incidence-low-among-canadian-men-prep_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> New cases of hepatitis C virus (HCV) infection among Canadian gay and bisexual men taking pre-exposure prophylaxis (PrEP) were uncommon compared with rates previously reported in Europe, according to research presented this week at the AASLD Liver Meeting in Boston. <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Liz Highleyman http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/hepatitis-c-incidence-low-among-canadian-men-prep_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ Epidemiology & behaviour HIV prevention policy Roger Pebody <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> How do we deal with apparent cases of PrEP failure? <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –>http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/how-do-we-deal-apparent-cases-prep-failure_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> The 17th European AIDS Conference (EACS 2019) in Basel, Switzerland, last week, heard about another case of a PrEP user who caught HIV despite being apparently adherent to PrEP. <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Gus Cairns http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/how-do-we-deal-apparent-cases-prep-failure_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ Epidemiology & behaviour HIV prevention policy Roger Pebody <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> 96-week results of DISCOVER PrEP trial presented at European AIDS Conference <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –>http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/96-week-results-discover-prep-trial-presented-european-aids-conference_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> The 96-week results of the DISCOVER trial, which compared the efficacy and safety of two different formulations of the antiretroviral drug tenofovir when used as daily PrEP by gay and bisexual men, were announced at the 17th European AIDS Conference (EACS 2019) in Basel last week. <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Gus Cairns http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/96-week-results-discover-prep-trial-presented-european-aids-conference_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ Epidemiology & behaviour HIV prevention policy Roger Pebody <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Options for two-drug simplification expand <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –>http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/options-two-drug-simplification-expand_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Further evidence on the efficacy of two-drug antiretroviral regimens as simplification options for people with suppressed viral load on three-drug regimens was presented last week at the 17th European AIDS Conference in Basel, Switzerland. <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Keith Alcorn http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/options-two-drug-simplification-expand_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ Epidemiology & behaviour HIV prevention policy Roger Pebody <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Tenofovir (TDF) does not increase risk of kidney disease in people at low risk <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –>http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/tenofovir-tdf-does-not-increase-risk-kidney-disease-people-low-risk_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ <!– THEME DEBUG –> <!– THEME HOOK: ‘views_view_field’ –> <!– BEGIN OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Antiretroviral treatment containing the older formulation of tenofovir (tenofovir disoproxil fumarate; TDF) did not increase the risk of chronic kidney disease in previously untreated people with HIV at low risk for kidney disease, a large American cohort study reported last week at the 17th European AIDS Conference in Basel, Switzerland. <!– END OUTPUT from ‘core/themes/stable/templates/views/views-view-field.html.twig’ –> Keith Alcorn http://www.aidsmap.com/__%3C%21–%20THEME%20DEBUG%20–%3E_%3C%21–%20THEME%20HOOK%3A%20%27views_view_field%27%20–%3E_%3C%21–%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E_/news//news/nov-2019/tenofovir-tdf-does-not-increase-risk-kidney-disease-people-low-risk_%3C%21–%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20–%3E__ Epidemiology & behaviour HIV prevention policy Roger Pebody
HIV news from aidsmap.com

Read More:  Harvard study suggests racial tension may stem from fear of exposure to infectious diseases